InvestorLens

LGND — LIGAND PHARMACEUTICALS INC

Public company

Sign in to save2 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying LGND?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Strong distribution · 0 buying vs 2 selling last quarter
4
Macro Tailwind
Macro conditions are mixed for this sector
52
Congressional Activity
1 congressional purchase, 0 sales disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their LGND position last quarter, 0 bought and 2 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 52/100 in a Overheat regime). 1 congressional purchase, 0 sales disclosed in the last 6 months.

Supporting evidence
  • +2 tracked investors reported holding LGND at their latest filing
Contradicting evidence — always shown
  • −2 tracked investors reduced or exited last quarter (0 reduced, 2 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 7/26/2026.

About LIGAND PHARMACEUTICALS INC (LGND)

LIGAND PHARMACEUTICALS INC (LGND) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $4M. Across recent filings, tracked investors recorded 1 new positions, 1 increased, 1 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in LGND

40
/100
Mixed Activity
Added / Increased2
Reduced1
Exited2
BearishBullish
Crowded Trade Score™

How many top investors track LGND

13
/100
Undiscovered
2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded
151015+

LGND Ownership Composition

How LIGAND PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Other
100% of tracked value
Institutions
2
tracked investors
Total Reported
$4M
combined 13F value
Sectors1
  • Other100.0%
Other(2)
100.0%

Tracked investors reporting LGND

  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    20K
    Value
    $4M
    % Portfolio
    0.00%
  • Ray DalioDec 31, 2025
    Bridgewater Associates
    Shares
    4.2K
    Value
    $795
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold LGND?
2 tracked institutional investors disclosed a position in LGND (LIGAND PHARMACEUTICALS INC) in their most recent 13F filing.
Who is the largest institutional holder of LGND?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in LGND, valued at $4M.
Did institutional ownership of LGND increase or decrease?
Across recent 13F filings, tracked investors recorded 1 new positions, 1 increased, 1 reduced, and 2 fully exited LGND.
Where does this LGND ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
LGND (LIGAND PHARMACEUTICALS INC) — Institutional Holders & — InvestorLens